Lenvatinib Plus PD-1 Antibody for Unresectable ICC

Overview

The purpose of this study is to evaluate the efficacy and safety of lenvatinib combined with PD-1 antibody for patients with unresectable intrahepatic cholangiocarcinoma.

Full Title of Study: “Lenvatinib Plus Programmed Cell Death Protein-1 (PD-1) Antibody for Unresectable Intrahepatic Cholangiocarcinoma”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: December 31, 2019

Interventions

  • Drug: Lenvatinib
    • 12 mg (or 8 mg) once daily (QD) oral dosing.
  • Drug: PD-1 antibody
    • 3mg/kg intravenously every 2 weeks

Arms, Groups and Cohorts

  • Experimental: Lenvatinib Plus PD-1
    • Participants received lenvatinib capsules 12 milligram (mg) based on the participant’s body weight greater than or equal to (>=) 60 kilogram (kg) or 8 mg based on the participant’s body weight less than (<) 60 kg at baseline, orally, once daily (QD) in continuous 14-day treatment cycles, and received 3mg/kg PD-1 antibody intravenously every 2 weeks up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.

Clinical Trial Outcome Measures

Primary Measures

  • Overall survival (OS)
    • Time Frame: 12 months
    • OS was defined as the duration from the date of randomization until the date of death from any cause. Participants who were lost to follow-up were censored at the last date the participant was known to be alive, and participants who remained alive were censored at the time of data cutoff.

Secondary Measures

  • Progression Free Survival (PFS)
    • Time Frame: 12 months
    • PFS was defined as the time from the date of randomization to the date of first documentation of disease progression based on modified Response Evaluation Criteria in Solid Tumors (mRECIST), or date of death, whichever occurred first.
  • Objective Response Rate (ORR)
    • Time Frame: 12 months
    • ORR was defined as the percentage of participants with a best overall response of complete response (CR) or partial response (PR) based on mRECIST. CR was defined as disappearance of any intratumoral arterial enhancement in all target lesions.
  • Adverse Events
    • Time Frame: 12 months
    • Number of adverse events. Postoperative adverse events were graded based on CTCAE v4.03

Participating in This Clinical Trial

Inclusion Criteria

  • The diagnosis of ICC
  • Patients must have at least one tumor lesion that can be accurately measured according to mRECIST criteria.
  • Chemotherapy resistance or patient refuse chemotherapy
  • No Cirrhosis or cirrhotic status of Child-Pugh class A only
  • Not amendable to surgical resection ,local ablative therapy and any other cured treatment.
  • Without distant metastasis, but intrahepatic lymph node metastasis is allowed
  • The following laboratory parameters:

Platelet count ≥ 50,000/μL Hemoglobin ≥ 8.5 g/dL Total bilirubin ≤ 30mmol/L Serum albumin ≥ 32 g/L ASL and AST ≤ 6 x upper limit of normal Serum creatinine ≤ 1.5 x upper limit of normal INR ≤ 1.5 or PT/APTT within normal limits Absolute neutrophil count (ANC) >1,500/mm3

Exclusion Criteria

  • Evidence of hepatic decompensation including ascites, gastrointestinal bleeding or hepatic encephalopathy
  • Known history of HIV
  • History of organ allograft
  • Known or suspected allergy to the investigational agents or any agent given in association with this trial.
  • Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy
  • Evidence of bleeding diathesis.
  • Patients with clinically significant gastrointestinal bleeding within 30 days prior to study entry.
  • Known central nervous system tumors including metastatic brain disease

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 75 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Shi Ming
  • Provider of Information About this Clinical Study
    • Sponsor-Investigator: Shi Ming, Clinical Professor – Sun Yat-sen University

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.